OBJECTIVE: Long-term therapy for anthrax might induce antimicrobial resistance in Bacillus anthracis. The aim of the present study was to investigate the potential of 18 different antibiotics to select resistant isolates of B. anthracis, (ST-1 and Sterne strains). METHODS: Resistant isolates were selected by serial passages on brain heart infusion agar containing increasing concentrations of antibiotics (from the MIC upwards). RESULTS: The MICs of ciprofloxacin, ofloxacin and levofloxacin increased from 0.125-0.25 to 8 mg/L, that of moxifloxacin increased from 0.03-0.06 to 8 mg/L, in both strains, and the MIC of garenoxacin increased from 0.015 to 0.5 mg/L for the ST-1 strain and from 0.03 to 8 mg/L for the Sterne strain. The MICs of tetracycline and minocycline increased from 0.125 to 2-8 mg/L and 0.06 to 1 mg/L, respectively. The MIC of vancomycin increased from 2.5 to 20 mg/L for the ST-1 strain and from 5 to 20 mg/L for the Sterne strain. Linezolid exhibited an MIC increase from 2 to 4 mg/L for both strains. The MIC of quinupristin/dalfopristin increased from 0.125 to 64-128 mg/L. Erythromycin demonstrated an MIC increase from 1 to 128 mg/L, that of clarithromycin increased from 0.125 to 8-64 mg/L and that of telithromycin increased from 0.06-0.125 to 1-4 mg/L. The clindamycin MIC increased from 0.125-0.25 to 8 mg/L. Penicillin G and amoxicillin MICs increased from <1 mg/L to 128-512 mg/L. Isolates made resistant to one fluoroquinolone exhibited cross-resistance to the other quinolones except the ST-1 mutant strain which remained susceptible to garenoxacin. Cross-resistance to fluoroquinolones did not correlate with resistance to other antibiotics. CONCLUSION: The ease with which B. anthracis can be made resistant in vitro suggests that close monitoring of patients treated for anthrax is mandatory.
OBJECTIVE: Long-term therapy for anthrax might induce antimicrobial resistance in Bacillus anthracis. The aim of the present study was to investigate the potential of 18 different antibiotics to select resistant isolates of B. anthracis, (ST-1 and Sterne strains). METHODS: Resistant isolates were selected by serial passages on brain heart infusion agar containing increasing concentrations of antibiotics (from the MIC upwards). RESULTS: The MICs of ciprofloxacin, ofloxacin and levofloxacin increased from 0.125-0.25 to 8 mg/L, that of moxifloxacin increased from 0.03-0.06 to 8 mg/L, in both strains, and the MIC of garenoxacin increased from 0.015 to 0.5 mg/L for the ST-1 strain and from 0.03 to 8 mg/L for the Sterne strain. The MICs of tetracycline and minocycline increased from 0.125 to 2-8 mg/L and 0.06 to 1 mg/L, respectively. The MIC of vancomycin increased from 2.5 to 20 mg/L for the ST-1 strain and from 5 to 20 mg/L for the Sterne strain. Linezolid exhibited an MIC increase from 2 to 4 mg/L for both strains. The MIC of quinupristin/dalfopristin increased from 0.125 to 64-128 mg/L. Erythromycin demonstrated an MIC increase from 1 to 128 mg/L, that of clarithromycin increased from 0.125 to 8-64 mg/L and that of telithromycin increased from 0.06-0.125 to 1-4 mg/L. The clindamycin MIC increased from 0.125-0.25 to 8 mg/L. Penicillin G and amoxicillin MICs increased from <1 mg/L to 128-512 mg/L. Isolates made resistant to one fluoroquinolone exhibited cross-resistance to the other quinolones except the ST-1 mutant strain which remained susceptible to garenoxacin. Cross-resistance to fluoroquinolones did not correlate with resistance to other antibiotics. CONCLUSION: The ease with which B. anthracis can be made resistant in vitro suggests that close monitoring of patients treated for anthrax is mandatory.
Authors: Katie J Molohon; Joel O Melby; Jaeheon Lee; Bradley S Evans; Kyle L Dunbar; Stefanie B Bumpus; Neil L Kelleher; Douglas A Mitchell Journal: ACS Chem Biol Date: 2011-10-06 Impact factor: 5.100
Authors: Robert Mabry; Mridula Rani; Robert Geiger; Gene B Hubbard; Ricardo Carrion; Kathleen Brasky; Jean L Patterson; George Georgiou; B L Iverson Journal: Infect Immun Date: 2005-12 Impact factor: 3.441
Authors: Linda M Weigel; David Sue; Pierre A Michel; Brandon Kitchel; Segaran P Pillai Journal: Antimicrob Agents Chemother Date: 2010-05-03 Impact factor: 5.191
Authors: Suresh K Tipparaju; Debbie C Mulhearn; Gary M Klein; Yufeng Chen; Subhasish Tapadar; Molly H Bishop; Shuo Yang; Juan Chen; Mahmood Ghassemi; Bernard D Santarsiero; James L Cook; Mary Johlfs; Andrew D Mesecar; Michael E Johnson; Alan P Kozikowski Journal: ChemMedChem Date: 2008-08 Impact factor: 3.466
Authors: Peter E Chen; Kristin M Willner; Amy Butani; Shakia Dorsey; Matroner George; Andrew Stewart; Shannon M Lentz; Christopher E Cook; Arya Akmal; Lance B Price; Paul S Keim; Alfred Mateczun; Trupti N Brahmbhatt; Kimberly A Bishop-Lilly; Michael E Zwick; Timothy D Read; Shanmuga Sozhamannan Journal: PLoS One Date: 2010-08-25 Impact factor: 3.240
Authors: Dylan Dodd; Joseph G Reese; Craig R Louer; Jimmy D Ballard; M Ashley Spies; Steven R Blanke Journal: J Bacteriol Date: 2007-05-11 Impact factor: 3.490